28 Sep, 2023, 07:30 ET Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023 Interim Analysis of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye Excellent Patient Safety and Tolerability Product …
22 Sep, 2023, 16:00 ET CRANBURY, N.J., Sept. 22, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted …
07 Sep, 2023, 16:00 ET CRANBURY, N.J., Sept. 7, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 …
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference Read More »
07 Sep, 2023, 07:30 ET Topline data currently expected late 4Q calendar 2023 Interim analysis of first 120 patients demonstrated: Excellent safety and tolerability product profile Potential for PL9643 to address multiple signs and symptoms of dry eye disease CRANBURY, N.J., Sept. 7, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing …
10 Aug, 2023, 07:30 ET ~30-40% of ED patients do not respond to PDE5i treatment Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Successfully co-formulated bremelanotide with a PDE5i Phase 2 clinical study in PDE5i non-responder ED patients currently expected to commence in 4Q 2023 CRANBURY, N.J., Aug. …
08 Aug, 2023, 07:30 ET First prescription dispensed in Chinese Hainan Province 93% of patients enrolled completed the Phase 3 trial in premenopausal patients with Hypoactive Sexual Desire Disorder (HSDD) in South Korea Data expected later this year Supports submission to Korean Ministry of Food & Drug Safety (MFDS) for Marketing Approval CRANBURY, N.J., Aug. …
07 Aug, 2023, 07:30 ET Partnership will increase hypoactive sexual desire disorder (HSDD) awareness and expand access to Vyleesi via UpScriptHealth’s Women’s Health Platform CRANBURY, N.J., Aug. 7, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, …
04 Aug, 2023, 07:30 ET CRANBURY, N.J., Aug. 4, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will participate at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 …
Palatin to Participate in Canaccord Genuity’s 43rd Annual Growth Conference Read More »
11 Jul, 2023, 07:30 ET $4.1 million in Gross Product Revenue 20% growth over 3Q23; 78% growth over 4Q22 $1.7 million in Net Product Revenue 42% growth over 3Q23; 122% growth over 4Q22 14% growth in prescriptions dispensed over 3Q23; 89% growth over 4Q22 6 consecutive quarters of double-digit growth 20% growth in new healthcare …
– Results demonstrate melanocortin agonists may represent a new therapeuticavenue to treat diabetic nephropathy – Open Label Phase 2 clinical study in diabetic kidney disease enrolling patients CRANBURY, N.J., May 30, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the …
